2023
A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma
Chen Y, Lin X, Zou X, Qian Y, Liu Y, Wang R, Wang X, Yu X, Liu C, Cheng H. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. BMC Gastroenterology 2023, 23: 113. PMID: 37024802, PMCID: PMC10080823, DOI: 10.1186/s12876-023-02748-w.Peer-Reviewed Original ResearchConceptsTumor-infiltrating immune cellsExpression of OX40Risk score modelImmune cellsIdentified OX40Immune checkpointsOverall survivalScoring systemRisk scoreClinical specimensExpression of immune checkpoint genesCD8+ T cellsImmune checkpoint gene expressionSomatic mutationsProtein expressionHigh-risk score groupImmunogenic cell deathCheckpoint gene expressionImmune checkpoint expressionImmune checkpoint genesImmune cell infiltrationNaive B cellsCox regression analysisAssociated with increased survival ratesRisk scoring system
2020
Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia
Wu C, Luedtke A, Sadikova E, Tsai H, Liao S, Liu C, Gau S, VanderWeele T, Kessler R. Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia. JAMA Network Open 2020, 3: e1921660. PMID: 32083693, PMCID: PMC7043195, DOI: 10.1001/jamanetworkopen.2019.21660.Peer-Reviewed Original ResearchConceptsFirst-episode schizophreniaAntipsychotic medicationPrescribed antipsychotic medicationTreatment success rateTreatment successSchizophrenic disordersFirst-episodeSuccess rateSchizophreniaProbability of treatment successTaiwan National Health Insurance Research DatabaseNational Health Insurance Research DatabaseHealth Insurance Research DatabaseEstimating treatment successValidation sampleIndividualized treatment rulesMedicationPrognostic studyPatientsInvestigated biomarkersClinical implementationDischarge diagnosisClinical observationsDemographic dataPragmatic trialKras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, Xu J, Yu X, Liu C. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Medicine 2020, 9: 2153-2159. PMID: 32017404, PMCID: PMC7064028, DOI: 10.1002/cam4.2895.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCD4 Lymphocyte CountCirculating Tumor DNADNA Mutational AnalysisFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsPolymerase Chain ReactionPrognosisProto-Oncogene Proteins p21(ras)Retrospective StudiesT-Lymphocytes, RegulatoryTime FactorsConceptsCell-free circulating tumor DNAAdvanced pancreatic cancer patientsPancreatic cancer patientsCirculating regulatory T cellsCirculating T-cell subsetsCA19-9 levelsRegulatory T cellsKRAS mutation statusT cell subsetsTumor-node-metastasisCancer patientsMutation statusTumor DNAKRAS mutationsT cellsAssociated with extremely poor survivalRegulatory T cell levelsAdvanced pancreatic cancerLevels of TregsProportion of TregsAbnormal immune statusCirculating tumor DNAT cell levelsPredicted worse prognosisTumor-node-metastasis stage
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2016
The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal Of Molecular Sciences 2016, 17: 1090. PMID: 27399694, PMCID: PMC4964466, DOI: 10.3390/ijms17071090.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesConceptsAdjuvant chemotherapyPostoperative survivalEGFR statusOverall survivalSurvival benefitEGFR expressionPancreatic cancerProlonged median overall survivalResected pancreatic cancer patientsAssociated with improved survivalSurgically resected pancreatic cancerMedian overall survivalResectable pancreatic cancerSignificant survival benefitEpidermal growth factor receptorKaplan-Meier analysisPancreatic cancer patientsPancreatic cancer treatmentStudies of EGFRGrowth factor receptorResectable PDACAdjuvant therapyPrognostic significanceImproved survivalExpression subgroups
2014
Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy
Luo G, Guo M, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X. Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Annals Of Surgical Oncology 2014, 22: 670-676. PMID: 25155401, DOI: 10.1245/s10434-014-4021-y.Peer-Reviewed Original ResearchConceptsNeutrophil-to-lymphocyte ratioBaseline neutrophil-to-lymphocyte ratioAdvanced pancreatic cancerNLR changeOverall survivalPancreatic cancerPrognostic roleMultivariate analysisPredictor of overall survivalSerum CA19-9 levelsPredictor of poor survivalAdvanced pancreatic adenocarcinomaCA19-9 levelsSerum albumin levelCox proportional hazards modelsProportional hazards modelPostchemotherapy changesClinicopathological predictorsDistant metastasisPrognostic factorsPancreatic adenocarcinomaClinicopathological characteristicsAlbumin levelsPoor survivalPredicting survivalThe combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
Wang W, Liu L, Xu H, Sun H, Wu C, Zhu X, Zhang W, Xu J, Liu C, Long J, Ni Q, Tang Z, Yu X. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget 2014, 5: 3895-3906. PMID: 25008315, PMCID: PMC4116529, DOI: 10.18632/oncotarget.2019.Peer-Reviewed Original ResearchConceptsSurvival of hepatocellular carcinomaMicrovessel densityHepatocellular carcinomaSorafenib treatmentDissemination of hepatocellular carcinomaAssociated with inhibition of angiogenesisAdvanced hepatocellular carcinomaMicrovessel density valuesCurative HCC resectionSuppressor of tumor growthInhibition of angiogenesisNegative prognostic indicatorAssociated with inhibitionSorafenib interventionHCC resectionSorafenib administrationOverall survivalDisease recurrencePrognostic factorsTissue microarrayPrognostic indicatorTumor growthSorafenibPersonalized treatmentPredictive value
2012
Management of a Malignant Case of Solid Pseudopapillary Tumor of Pancreas
Ji S, Xu J, Zhang B, Xu Y, Liu C, Long J, Ni Q, Yu X. Management of a Malignant Case of Solid Pseudopapillary Tumor of Pancreas. Pancreas 2012, 41: 1336-1340. PMID: 22699200, DOI: 10.1097/mpa.0b013e31824d52c7.Peer-Reviewed Original ResearchConceptsSolid pseudopapillary tumorMalignant SPTPseudopapillary tumorCase of solid pseudopapillary tumorCases of metastasisUnresectable tumorsExcellent prognosisMalignant potentialClinicopathological featuresSurgical removalMalignant casesTumorYoung femalesPancreasRadiotherapyChemotherapyMetastasisNeoplasmsPrognosisRecurrencePatientsCases
2011
Therapeutic and prognostic importance of epithelial–mesenchymal transition in liver cancers: Insights from experimental models
Ogunwobi O, Liu C. Therapeutic and prognostic importance of epithelial–mesenchymal transition in liver cancers: Insights from experimental models. Critical Reviews In Oncology/Hematology 2011, 83: 319-328. PMID: 22178416, DOI: 10.1016/j.critrevonc.2011.11.007.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionHepatocellular carcinomaHepatic metastasesPrognostic importanceExperimental modelColon cancerTreatment of patientsRole of EMTHuman cancer patientsPotential therapeutic targetHuman malignant diseaseSignificant morbidityCancer patientsMalignant diseaseMalignant conditionsLiver cancerTherapeutic targetBasic scientistsCancerFurther studiesPatientsCarcinomaMetastasisLiverHuman tissues